The Rare Cancer Research Foundation (RCRF) is committed to accelerating research and improving outcomes for people facing rare cancers. By empowering patients to participate in research and share their data, RCRF helps break down the barriers that often slow progress in rare disease science.

Through a collaborative and mission-driven partnership, cureMEC and RCRF have launched the first-ever MEC BioBank and MEC Patient Registry—critical resources that support research into myoepithelial carcinoma (MEC).This groundbreaking effort gives patients a meaningful way to contribute to research by donating tissue and fluid samples and sharing their medical histories. These contributions provide scientists with the tools they need to better understand MEC and explore new treatment possibilities.

By combining cureMEC’s focus on the MEC community with RCRF’s expertise in decentralized, patient-driven studies, this partnership is opening new doors to discovery—and bringing hope to patients and families affected by MEC.

CANCollaborate is a coalition of rare cancer nonprofits working together to accelerate research and improve outcomes for patients facing rare and understudied cancers. As a proud member of this dynamic network, cureMEC gains access to a wealth of collective knowledge, strategic insight, and cross-disease collaboration. 

CANCollaborate has played a key advisory role in shaping our organizational direction and has helped us forge meaningful connections with leading institutions, researchers, and nonprofit partners. Through this alliance, we’re opening new pathways for growth, advocacy, and impact in the fight against myoepithelial carcinoma.

The Rally Foundation for Childhood Cancer Research is one of the leading funders of pediatric cancer research in the United States, driven by a mission to support innovative, less toxic treatments for children battling cancer.

cureMEC is proud to have partnered with Rally on multiple occasions to support and advance cutting-edge research in myoepithelial carcinoma (MEC).

Rally’s strong reputation and robust funding model enable us to jointly support bold, early-stage research that might otherwise go unfunded—helping accelerate meaningful progress in MEC research.

The TargetCancer Foundation is dedicated to rare cancers with limited treatment options, driving innovative research and fostering collaboration across scientists, clinicians, advocacy groups, and patients.

As a trusted collaborator, TargetCancer has played an important role in shaping cureMEC’s strategic direction, offering valuable insight into nonprofit-driven research models that prioritize patient impact.

Their innovative approach to funding, clinical trial design, and patient education has informed how we advocate, invest, and grow. Together, we’re working to amplify the urgency of rare cancer research and accelerate progress for patients with myoepithelial carcinoma.

cureMEC is proud to serve as an official Advocacy Partner of the National Cancer Institute’s MyPART (My Pediatric and Adult Rare Tumor) Network. The MyPART program brings together patients, families, advocates, clinicians, and researchers to accelerate progress in understanding and treating rare tumors.

As part of this national network, cureMEC helps bridge the gap between patients and research—sharing information about clinical trials, providing educational resources, and ensuring that the voices of those affected by myoepithelial carcinoma are heard in the research process. Through this partnership, we work to raise awareness, foster collaboration, and advance meaningful discoveries that improve outcomes for individuals and families facing rare cancers.